Similarly, another study of influenza patients aged 1-12 years showed that neuraminidase inhibitor
treatment reduced the duration of their illness by 1.
The adamantanes are ineffective against influenza B viruses, which limits the available antiviral options to 2 neuraminidase inhibitors
(NAIs), inhaled zanamivir and oral oseltamivir.
Comment: Tamiflu is one of two available neuraminidase inhibitors
, which work by blocking the influenza enzyme that promotes viral release from infected cells.
And resistant viruses produced with neuraminidase inhibitor
use appear to have reduced virulence.
Position statement: global neuraminidase inhibitor
was not involved in the studies but has studied Tamiflu and Relenza (zanamivir), the other available neuraminidase inhibitor
, which is in a dry powder inhalation formulation.
Evaluation of neuraminidase enzyme assays using different substratcs to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors
: report of the neuraminidase inhibitor
BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor
for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor forhematological malignancies.
A national survey of the Infectious Diseases Society of America Emerging infections Network concerning neuraminidase inhibitor
prescription practices and pandemic influenza preparations.
Oral oseltamivir, a neuraminidase inhibitor
, may be a safe and effective prophylaxis against influenza, based on combined results of two controlled trials.
To the Editor: Oseltamivir is a neuraminidase inhibitor
approved for treatment and prevention of influenza virus infection.
Treanor, an investigator in studies of Relenza and an oral neuraminidase inhibitor
manufactured by Roche, which may also be approved in time for this flu season.
Given the high cost and limited supply of neuraminidase inhibitor
antiviral drugs and an uncertain supply and effectiveness of future vaccines, only 12 (25%) states plan or consider using either chemoprophylaxis (such as oseltamivir) or vaccination of household and other close nonhospital contacts in their plans to retard epidemic influenza.
Roche is developing an oral neuraminidase inhibitor
Biota developed the first-in-class neuraminidase inhibitor
, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.